Here’s a link to Echo Therapeutics (OTCBB: ECTE) CEO Patrick H. Mooney, M.D’s presentation this week at the OneMed Finance Forum in San Francisco: http://www.ustream.tv/recorded/3953983

This gives a gret description of the company, its key products/technologies, and core markets in a quick and understandable preso. Judging from this update, things are certainly looking up for Echo this year. Enjoy!

Leading healthcare executives and institutional finance firms will embark upon San Francisco next week in search of “the next best thing” in the medical field. Luckily for them, Echo Therapeutics (OTCBB: ECTE) will be there to give it to them.

(more…)

As some readers have mentioned recently, Echo Therapeutics, Inc. (OTCBB: ECTE) is showing a great deal of promise to surpass many of its competitors over the next 12 to 24 months, both with regard to market penetration, sales, and PPS. DexCom, Inc. (NASDAQ: DXCM) is trading at nearly $8 per share despite logging only $9.8M in 2008 revenues and annual net income of ($55.2M). While the company’s “SEVEN” CGM product is FDA-approved, Echo’s “Symphony” system is stronger in many regards.

(more…)

Echo Therapeutics is a transdermal medical device and specialty pharmaceuticals company. Echo’s Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets.

Echo’s AzoneTS™ transdermal drug reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA’s Section 505(b)(2) guidelines. Durhalieve™, Echo’s lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA.

Echo Therapeutics, Inc. (OTCBB: ECTE) gained 9.6% or $.12 today on nearly 98,000 shares traded after analyst firm Boenning & Scattergood issued an “outperform” rating on the company along with a 12-month price target of $3.

(more…)

Echo Therapeutics, Inc. (OTCBB:ECTE),  a medical device and specialty pharmaceutical company, is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, and for people with diabetes and a wide range of transdermal reformulations of specialty pharmaceutical products previously approved by the United States Food and Drug Administration. It offers Symphonytm tCGM System, a next-generation, non-invasive (needle-free), wireless tCGM system designed to provide on-demand blood glucose data. The company was founded in 1989 and is based in Franklin, Massachusetts.

For more information, visit: http://www.echotx.com/